Clinical Trial Update: BR55 in Characterization of Ovarian Lesions [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the BR55 ultrasound contrast agent for characterizing ovarian lesions in ovarian cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BR55

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19